These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7554035)

  • 21. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study.
    Murakami H; Tamura T; Yamada Y; Yamamoto N; Ueda Y; Shimoyama T; Saijo N
    Eur J Cancer; 2002 Dec; 38 Suppl 8():S1-5. PubMed ID: 12645906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
    Latif T; Wood L; Connell C; Smith DC; Vaughn D; Lebwohl D; Peereboom D
    Invest New Drugs; 2005 Jan; 23(1):79-84. PubMed ID: 15528984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on satraplatin: the first orally available platinum anticancer drug.
    Kelland LR
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
    Sessa C; Capri G; Gianni L; Peccatori F; Grasselli G; Bauer J; Zucchetti M; Viganò L; Gatti A; Minoia C; Liati P; Van den Bosch S; Bernareggi A; Camboni G; Marsoni S
    Ann Oncol; 2000 Aug; 11(8):977-83. PubMed ID: 11038034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
    Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
    Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
    Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E; de Vries EG; Meijer S; Groen HJ
    Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
    Ribaud P; Gouveia J; Misset JL; Mathé G
    Oncology; 1986; 43(2):78-82. PubMed ID: 3951788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI; Odell DE; Kelland LR
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
    Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
    Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
    Ota K; Oguma T; Shimamura K
    Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
    Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
    Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.